Berlin: European stocks rebounded yesterday after four days of declines as Ukraine accepted a ceasefire proposal brokered by the US, while data ...

DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an inhibitor of the ...

In what it says is the biggest obesity deal to date, Zealand Pharma A/S has signed up Roche AG to a potential $5.3 billion ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

Christine Lagarde, president of the ECB, warned that abrupt changes in global trade and the region's defense system will make ...

Profits and losses for petrelintide and the petrelintide/CT-388 combination will be shared on a 50:50 basis in the U.S. and Europe, while Zealand will be eligible to receive tiered double-digit ...

European shares rebounded on optimism over developments in the Ukraine-Russia conflict and a cooler U.S. inflation report. A ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

A consortium consisting of Warburg Pincus and KKR are in talks to acquire German medical packaging maker Gerresheimer AG , ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.